AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22868877 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no treatment)
Number of subjects: 23
Study 22868877 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with amisulpride
Number of subjects: 23
Study 22869821 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal systolic strain (GLS) quartiles
Number of subjects: 125
Study 22869821 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal systolic strain (GLS)
Number of subjects: 125
Study 22869821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model containing GLS
Number of subjects: 125
Study 22869824 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 0
Study 22869824 — intervention group
Group type: COMPARATOR
Intervention: HIV-exposed uninfected neonates (HEU)
Number of subjects: 0
Study 22869824 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected newborns
Number of subjects: 0
Study 22871021 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 50 μg twice per day (BID) for 14 days
Number of subjects: 5
Study 22871230 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer metabolic system model for insulin infusion rates; short-term trials (24 hours) on 8 infants.
Number of subjects: 30
Study 22871230 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer metabolic system model for insulin infusion rates; long-term trials on 22 infants.
Number of subjects: 30
Study 22871230 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusions determined by sliding scales and clinician intuition; retrospective cohort of 21 patients.
Number of subjects: 30
Study 22871833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic eyes (PGE2 levels)
Number of subjects: 26
Study 22871833 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic eyes (PGE2 levels)
Number of subjects: 26
Study 22871833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic eyes (VEGF levels)
Number of subjects: 26
Study 22871833 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic eyes (VEGF levels)
Number of subjects: 26
Study 22871833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic eyes (other cytokines)
Number of subjects: 26
Study 22871833 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PGE2 with IP-10 and VEGF
Number of subjects: 26
Study 22872673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium
Number of subjects: 0
Study 22872673 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22872731 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal trivalent inactivated influenza vaccine (TIV)
Number of subjects: 1116
Study 22872731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010-2011 split TIV
Number of subjects: 1116
Study 22872731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2011-2012 split TIV
Number of subjects: 1116
Study 22872731 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted TIV
Number of subjects: 1116
Study 22872731 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjuvanted subunit TIV
Number of subjects: 1116
Study 22873533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular assist device (specific device for children)
Number of subjects: 48
Study 22873637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail sedation (propofol, meperidine, midazolam)
Number of subjects: 205
Study 22873637 — intervention group
Group type: COMPARATOR
Intervention: Conventional sedation (meperidine, midazolam)
Number of subjects: 205
Study 22873940 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety and concern
Number of subjects: 500
Study 22873940 — intervention group
Group type: EXPERIMENTAL
Intervention: CMD-SQ, EQ-5D, SF-12, HVOK, RCS, OHS/OSS questionnaires
Number of subjects: 500
Study 22874520 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-exposed group
Number of subjects: 60
Study 22874520 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22874599 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 2455
Study 22874599 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy/resection
Number of subjects: 2455
Study 22875136 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiretinal membrane removal surgery
Number of subjects: 52
Study 22875626 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (30 mg/kg/day)
Number of subjects: 6
Study 22875626 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (40 mg/kg/day)
Number of subjects: 6
Study 22875626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of deferasirox and deferoxamine
Number of subjects: 6
Study 22875627 — intervention group
Group type: EXPERIMENTAL
Intervention: IKZF1 deletions
Number of subjects: 694
Study 22875883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ultrasmall superparamagnetic particles of iron oxide (4 mg/kg)
Number of subjects: 16
Study 22875883 — intervention group
Group type: COMPARATOR
Intervention: No infusion (control)
Number of subjects: 16
Study 22877812 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CRP levels
Number of subjects: 785
Study 22877866 — intervention group
Group type: EXPERIMENTAL
Intervention: GCSF-mobilized CD34+ cell therapy
Number of subjects: 17
Study 22878519 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-690514 100 mg
Number of subjects: 9
Study 22878519 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-690514 200 mg
Number of subjects: 9
Study 22878551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric, isonitrogenous nutrition administered via intravenous infusion of glucose with amino acids over 72 hours (24 hours before to 48 hours after surgery). Glucose provided 50% and amino acids provided 20% of the patient's measured resting energy expenditure.
Number of subjects: 17
Study 22878784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal polysomnography with transcutaneous capnography
Number of subjects: 46
Study 22878784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 46
Study 22880942 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (0.3 mg/kg for <6 years, 20 mg or 40 mg tablets for ≥6 years)
Number of subjects: 24
Study 22882209 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum vascular endothelial growth factor (s-VEGF) levels
Number of subjects: 102
Study 22882209 — intervention group
Group type: COMPARATOR
Intervention: Low serum vascular endothelial growth factor (s-VEGF) levels
Number of subjects: 102
Study 22883224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1001
Study 22883224 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1001
Study 22883549 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft reinterventions in adults
Number of subjects: 2023
Study 22883549 — intervention group
Group type: EXPERIMENTAL
Intervention: Homograft reinterventions in adults
Number of subjects: 2023
Study 22883549 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft reinterventions in pediatric population
Number of subjects: 2023
Study 22883549 — intervention group
Group type: EXPERIMENTAL
Intervention: Homograft reinterventions in pediatric population
Number of subjects: 2023
Study 22883549 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for shorter time to reoperation
Number of subjects: 2023
Study 22883549 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocarditis as a reason for reintervention
Number of subjects: 2023
Study 22883691 — intervention group
Group type: EXPERIMENTAL
Intervention: New research criteria diagnosis combining clinical and biomarker information
Number of subjects: 241
Study 22883691 — intervention group
Group type: COMPARATOR
Intervention: Clinical practice diagnosis at baseline using clinical information only (no biomarkers)
Number of subjects: 241
Study 22883691 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic model combining evidence from the study, literature, and expert opinion
Number of subjects: 241
Study 22883740 — intervention group
Group type: EXPERIMENTAL
Intervention: IV treprostinil
Number of subjects: 3518
Study 22883740 — intervention group
Group type: COMPARATOR
Intervention: IV epoprostenol
Number of subjects: 3518
Study 22884544 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Shoe (SS) with Flat Insole (FI)
Number of subjects: 10
Study 22884544 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Shoe (SS) with Carbon Fiber Insole (CFI)
Number of subjects: 10
Study 22884544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker Sole Shoe (RSS) with Flat Insole (FI)
Number of subjects: 10
Study 22884544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker Sole Shoe (RSS) with Carbon Fiber Insole (CFI)
Number of subjects: 10
Study 22884544 — intervention group
Group type: COMPARATOR
Intervention: Barefoot condition
Number of subjects: 10
Study 22884685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2mg/day)
Number of subjects: 69
Study 22884788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 0
Study 22884879 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1083801 within the GRM7 gene (GG genotype)
Number of subjects: 1541
Study 22885015 — intervention group
Group type: EXPERIMENTAL
Intervention: Focetria (vaccinated group)
Number of subjects: 127522
Study 22885015 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated group (control)
Number of subjects: 127522
Study 22885330 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNα-2a and RBV) for 4 weeks, followed by PegIFNα-2a and RBV until week 48
Number of subjects: 5
Study 22885330 — intervention group
Group type: COMPARATOR
Intervention: TMC435 (200 mg once daily) as monotherapy for 5 days
Number of subjects: 5
Study 22887690 — intervention group
Group type: EXPERIMENTAL
Intervention: 320-row detector computed tomography (CT)
Number of subjects: 208
Study 22887690 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary angiography and single-photon emission CT myocardial perfusion imaging (gold standard)
Number of subjects: 208
Study 22887757 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative fasting blood glucose (FBG) screening
Number of subjects: 275
Study 22888091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiograph (CXR) reading by pediatric radiologists
Number of subjects: 803
Study 22888091 — intervention group
Group type: EXPERIMENTAL
Intervention: CXR reading by pediatric radiologists
Number of subjects: 803
Study 22889943 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with anemia targets (Hb 11.0-12.0 g/dl, transferrin saturation ratio ≥20%, ferritin 100-500 ng/ml)
Number of subjects: 598
Study 22890635 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cerebral infarction
Number of subjects: 327
Study 22890635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical deterioration
Number of subjects: 327
Study 22891258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest third HDL-C level
Number of subjects: 11140
Study 22892757 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity assessment
Number of subjects: 606
Study 22892888 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish CLS; Sensimed AG, during two 24-hour IOP monitoring sessions (S1 and S2) at a 1-week interval.
Number of subjects: 40
Study 22892888 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish CLS; Sensimed AG, for patients not on glaucoma medication.
Number of subjects: 40
Study 22892888 — intervention group
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish CLS; Sensimed AG, for patients on glaucoma medication.
Number of subjects: 40
Study 22892888 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during monitoring with the contact lens sensor.
Number of subjects: 40
Study 22892888 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility assessment using Pearson correlations.
Number of subjects: 40
Study 22892920 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 25 mg, administered orally
Number of subjects: 5
Study 22892922 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔRESP PP ≥ 10%
Number of subjects: 37
Study 22892922 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔRESP PP adjustment for driving pressure
Number of subjects: 37
Study 22892922 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔRESP PP ≥ 10% in septic shock patients
Number of subjects: 37
Study 22894138 — intervention group
Group type: EXPERIMENTAL
Intervention: ASUKI Step pedometer intervention
Number of subjects: 2118
Study 22894607 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment in mice bearing PDAC xenografts
Number of subjects: 0
Study 22894607 — intervention group
Group type: EXPERIMENTAL
Intervention: SP analysis through whole-genome expression profiling
Number of subjects: 0
Study 22894607 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro analysis of SP and MP
Number of subjects: 0
Study 22894827 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept treatment (25 mg biweekly for 2 weeks)
Number of subjects: 20
Study 22894884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus fotemustine
Number of subjects: 86
Study 22895887 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy
Number of subjects: 13
Study 22896000 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous omacetaxine 1.25 mg/m² twice daily, days 1-14, every 28 days until hematologic response or a maximum of 6 cycles, then days 1-7 every 28 days as maintenance
Number of subjects: 62
Study 22896000 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous omacetaxine 1.25 mg/m²
Number of subjects: 62
Study 22897944 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib 50 mg/day (4 weeks on treatment, 2 weeks off treatment)
Number of subjects: 61
Study 22897964 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. busulfan (BU) 9.6 mg/kg plus melphalan 140 mg/m² (MEL140)
Number of subjects: 153
Study 22897964 — intervention group
Group type: COMPARATOR
Intervention: Melphalan 200 mg/m² (MEL200)
Number of subjects: 153
Study 22897964 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. busulfan plus melphalan
Number of subjects: 153
Study 22897964 — intervention group
Group type: COMPARATOR
Intervention: Melphalan 200 mg/m²
Number of subjects: 153
Study 22898044 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 28
Study 22899582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lenalidomide 25 mg Days 1-21 with a 7-day break after each cycle
Number of subjects: 18
Study 22899766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC) levels
Number of subjects: 823
Study 22900504 — intervention group
Group type: EXPERIMENTAL
Intervention: UC781 (0.1, 0.25%) gel
Number of subjects: 0
Study 22901459 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab, 150 mg subcutaneously every 8 weeks for 6 months
Number of subjects: 1
Study 22901459 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab, resumed after flare
Number of subjects: 1
Study 22901459 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 1
Study 22901741 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal UCDs (CPSD or OTCD)
Number of subjects: 103
Study 22901741 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal UCDs (ASD or ALD)
Number of subjects: 103
Study 22901741 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSD or OTCD
Number of subjects: 103
Study 22901741 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD
Number of subjects: 103
Study 22901741 — intervention group
Group type: EXPERIMENTAL
Intervention: ALD
Number of subjects: 103
Study 22901741 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSD/OTCD
Number of subjects: 103
Study 22901847 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) treatment with SC injections of leuprolide acetate (LA; Procren 3.75 mg every 28th day)
Number of subjects: 15
Study 22901847 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) treatment
Number of subjects: 15
Study 22901847 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment observation
Number of subjects: 15
Study 22901847 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison with healthy age-matched girls
Number of subjects: 15
Study 22901847 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison with Tanner-matched girls
Number of subjects: 15
Study 22902483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy during pregnancy (median of four cycles, range one to eight); 197 women received chemotherapy, including 178 with anthracycline, 15 with cyclophosphamide, methotrexate, and fluorouracil, and 14 with taxane.
Number of subjects: 447
Study 22902483 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in utero
Number of subjects: 447
Study 22902483 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born before 37 weeks of gestation
Number of subjects: 447
Study 22902483 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting chemotherapy during pregnancy
Number of subjects: 447
Study 22902761 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy with adenoma detection rates in the lowest quartile (2.0%-7.2%)
Number of subjects: 46835
Study 22902761 — intervention group
Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy with adenoma detection rates in higher quartiles (above 7.2%)
Number of subjects: 46835
Study 22902761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of distal adenoma detection (<7.2%)
Number of subjects: 46835
Study 22903006 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite PHT (defined by history of complication or clinical findings consistent with PHT)
Number of subjects: 163
Study 22903006 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible PHT (one finding present without complication)
Number of subjects: 163
Study 22903006 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent PHT (none of the criteria met)
Number of subjects: 163
Study 22903006 — intervention group
Group type: COMPARATOR
Intervention: Definite PHT vs Absent PHT
Number of subjects: 163
Study 22903006 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite PHT
Number of subjects: 163
Study 22903331 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction intervention
Number of subjects: 0
Study 22903331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22904181 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT with 250-μg cosyntropin injection
Number of subjects: 1
Study 22904181 — intervention group
Group type: COMPARATOR
Intervention: Baseline 18F-FDG PET/CT scan
Number of subjects: 1
Study 22904181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian venous sampling after cosyntropin administration
Number of subjects: 1
Study 22904181 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative androgen concentrations
Number of subjects: 1
Study 22905781 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio messages broadcasted during peak hours (12.00-14.00 and 18.00-23.00)
Number of subjects: 1628
Study 22905781 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the radio at different times
Number of subjects: 1628
Study 22906363 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial tidal volume (VT) < 8 mL/kg predicted body weight (PBW)
Number of subjects: 829
Study 22906363 — intervention group
Group type: COMPARATOR
Intervention: Initial tidal volume (VT) ≥ 8 mL/kg predicted body weight (PBW)
Number of subjects: 829
Study 22906363 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial tidal volume (VT)
Number of subjects: 829
Study 22906363 — intervention group
Group type: COMPARATOR
Intervention: Initial tidal volume (VT) ≥ 8 mL/kg PBW
Number of subjects: 829
Study 22906363 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intubation ALI/ARDS
Number of subjects: 829
Study 22907176 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention over 6 months
Number of subjects: 0
Study 22909164 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human C1 inhibitor (rhC1-INH) 2100 U
Number of subjects: 57
Study 22909342 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (2 MIU/day for 14 days)
Number of subjects: 6
Study 22909342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive cell therapy with TIL infusion
Number of subjects: 6
Study 22909342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adoptive cell therapy and low-dose IL-2
Number of subjects: 6
Study 22910104 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of apremilast orally twice daily for 12 weeks
Number of subjects: 10
Study 22910448 — intervention group
Group type: EXPERIMENTAL
Intervention: Current depressive symptoms
Number of subjects: 823
Study 22910448 — intervention group
Group type: EXPERIMENTAL
Intervention: History of depression
Number of subjects: 823
Study 22910448 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for gender and physical activity
Number of subjects: 823
Study 22910894 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ischemic lesion patterns of subcorticocortical lesions
Number of subjects: 353
Study 22910894 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ischemic lesion patterns of multiple lesions
Number of subjects: 353
Study 22910894 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ischemic lesion patterns (subcorticocortical and multiple lesions)
Number of subjects: 353
Study 22910894 — intervention group
Group type: EXPERIMENTAL
Intervention: New ischemic lesions
Number of subjects: 353
Study 22910894 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical recurrent stroke
Number of subjects: 353
Study 22911183 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 250 mg/d, increased to 500 mg/d after 2 months if new blisters continued to develop
Number of subjects: 10
Study 22911442 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 radioembolization (Y90RE)
Number of subjects: 52
Study 22911697 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV co-infection
Number of subjects: 3441